ARS Pharmaceuticals, Inc. (SPRY)
4.02
-0.05
(-1.23%)
USD |
NASDAQ |
Oct 16, 16:00
4.02
0.00 (0.00%)
After-Hours: 20:00
ARS Pharmaceuticals Research and Development Expense (Annual) : 13.18M for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | 13.18M |
| December 31, 2024 | 19.58M |
| December 31, 2023 | 20.27M |
| December 31, 2022 | 18.38M |
| Date | Value |
|---|---|
| December 31, 2021 | 20.27M |
| December 31, 2020 | 23.94M |
| December 31, 2019 | 21.50M |
| December 31, 2018 | 14.80M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| Capricor Therapeutics, Inc. | 83.50M |
| Sionna Therapeutics, Inc. | 60.26M |
| Nektar Therapeutics | 117.07M |
| Ardelyx, Inc. | 68.47M |
| Kyntra Bio, Inc. | 23.52M |